Contact Us
News

Olon announces the completion of the investment to expand the pilot plant capacity in Rodano plant

How can a few microorganisms shape our future helping to upgrade some of the most polluting parts of our economy?

MIKE H. O’NEILL, Director, Analytical Chemistry at Olon Ricerca Bioscience LLC, gave a scientific lecture about Analytical Chemistry in Early-Stage Drug Development at Case Western Reserve University, US. 
The presentation gave an overview of the drug development process noting some of the key developmental milestones, introducing also some of the common types of analytical technologies used during development of small molecule active pharmaceutical ingredients. The talk highlighted the importance of Solid-Form screening which aims to improve the physicochemical properties and developability of nascent drug candidates.MIKE H. O’NEILL, Director, Analytical Chemistry at Olon Ricerca Bioscience LLC, gave a scientific lecture about Analytical Chemistry in Early-Stage Drug Development at Case Western Reserve University, US. The presentation gave an overview of the drug development process noting some of the key developmental milestones, introducing also some of the common types of analytical technologies used during development of small molecule active pharmaceutical ingredients. The talk highlighted the importance of Solid-Form screening which aims to improve the physicochemical properties and developability of nascent drug candidates.
Mike’s team is responsible for characterization of active pharmaceutical ingredients, method development, preformulation, stability, quality control, and solid-state form screening.  Mike has been named as an inventor on more than 35 patent applications regarding the solid forms of drugs and processes to control drug characteristics. 

 Olon is pleased to announce the completion of the investment in its Rodano facility to expand the pilot plant capacity of scaling up highly active API, up to level of containment OEB5 (1-0.1 ug/m3). 
Indeed, Olon is supported by other pilot plants in the development of high-potency APIs (like Segrate) with which the Rodano plant will be integrated for increased capacity and improved flexibility.
The investment is part of a consolidated strategy by Olon, which envisages the implementation of a highly integrated operating model between both R&D and manufacturing operations and the integration of specific, highly specialized processes consolidated within research and development centers located in sites around the world. 
This integration will also be applied to product scale-up projects, which require the transition from pilot plants to large- and very large-scale production plants that have similar equipment such as to ensure the same level of containment even for large batch sizes.
Olon has in fact developed one of the most advanced and flexible high-containment API production platforms on the market.
 


Mike’s team is responsible for characterization of active pharmaceutical ingredients, method development, preformulation, stability, quality control, and solid-state form screening.  Mike has been named as an inventor on more than 35 patent applications regarding the solid forms of drugs and processes to control drug characteristics.